Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
09/2003
09/30/2003US6627194 Activated immunoglobulin
09/30/2003US6626932 Therapeutic light source and method
09/30/2003CA2254750C Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2108788C Liposomal prostaglandin formulations
09/30/2003CA2102697C Pyrrolidine derivatives, preparation thereof and drugs containing same
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078465A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
09/25/2003WO2003078457A1 MUTEINS OF THE C5a ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5a ANAPHYLATOXIN
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078422A1 Novel pyridone derivative
09/25/2003WO2003078421A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078419A1 N-substituted benzothiophenesulfonamide derivative
09/25/2003WO2003078416A1 Therapeutic ion channel blocking agents and methods of use thereof
09/25/2003WO2003078409A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
09/25/2003WO2003078408A1 Crystalline parecoxib sodium
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003077947A1 Methods of modulating cd200 receptors
09/25/2003WO2003077922A1 Composition in an aqueous gel state, method for the production and use thereof in the production of a medicament, in particular an antiherpetic medicament
09/25/2003WO2003077920A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077916A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077907A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003WO2003077893A2 Compositions for treating digestive functional pathologies
09/25/2003WO2003077863A2 Method for overexpression of zwitterionic polysaccharides
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077830A2 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives
09/25/2003WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003015690A3 Method for treating primary insomnia
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2003000709A3 Sialic acid derivatives for use as siglec inhibitors
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002094282A3 Compositions with methylprednisolone derivatives having therapeutic effect
09/25/2003WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002026982A3 Secreted human proteins
09/25/2003WO2002015922A3 New uses for amino acid anticonvulsants for treatment of pain
09/25/2003WO2002014489A9 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
09/25/2003US20030181706 Inflammation-associated polynucleotides
09/25/2003US20030181687 Heparanase activity neutralizing anti-heparanase monoclonal antibody
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181515 Administering to a subject in need of pain relief a medicinal ointment comprising an active kavalactone selected from the group consisting of dihydrokawain, dihydromethysticin, kawain and medicinally acceptable carrier
09/25/2003US20030181514 Therapeutic compounds and methods
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181501 Therapy and prophylaxis of cyclooxygenase-2 mediated conditions and disorders
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181472 Inflammation modulators
09/25/2003US20030181471 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
09/25/2003US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181420 Modulators of LXR
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181400 Novel disaccharides with anti-arthrosic properties
09/25/2003US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181362 Receptor
09/25/2003US20030181359 Tripeptide prodrug compounds
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180931 Cellubrevin homologs
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180810 For diagnosis, prevention, and treatment of reproductive disorders, Alzheimer's disease, cancer, immunological disorders, and diabetes
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180786 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/25/2003US20030180752 Type 2 cytokine receptor and nucleic acids encoding same
09/25/2003US20030180744 High affinity oligonucleotide ligands to growth factors
09/25/2003US20030180405 For cosmstics, drugs; antiinflamamtory agents; oxidation resistance
09/25/2003US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
09/25/2003US20030180395 Anxiolytic agents; analgesics; sleep disorders; antiinflammatory agents; central nervous system disorders
09/25/2003US20030180386 Aqueous metal bicarbonate solution and method of use
09/25/2003US20030180362 Multi-stage oral drug controlled-release system
09/25/2003US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180275 Human serpin polypeptides
1 ... 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 ... 1272